Top

BMC Pulmonary Medicine

Published in:

01-12-2020 | Lung Cancer | Research article

Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Authors: Tian Fu, Yong Lin, Qingdi Zeng, Wei Yao, Liping Han

Published in: BMC Pulmonary Medicine | Issue 1/2020

Abstract

Background

Tumor necrosis factor (TNF) has been investigated to be correlated with the occurrence and progression of lung cancer. This investigation was to assess the efficacy and safety of recombinant mutant human tumor necrosis factor (rmhTNF) for controlling malignant pleural effusion (MPE) through thoracic perfusion.

Methods

Through searching from MEDLINE, Web of Science, EMBASE, Cochrance Library, OVID and China National Knowledge Infrastructure (CNKI), a total of 12 studies with 694 patients were included in this study. A series of meta-analysis methods were used to analyze the extracted data.

Results

Thoracic perfusion of rmhTNF combined with cisplatin promoted the objective response rate (ORR) (P < 0.001; odds ratio = 4.49) and the quality of life (QOL) of patients with MPE (P < 0.001; odds ratio = 10.33), as compared with cisplatin alone. Although the participation of rmhTNF increased the incidence of fever (P < 0.001), it seemed to relieve the adverse reactions in the digestive tract (P = 0.017).

Conclusions

Thoracic perfusion of rmhTNF contributes to the treatment of MPE and improves the QOL of MPE patients.

Kastelik JA. Management of malignant pleural effusion. Lung. 2013;191(2):165–75.PubMed

Desai NR, Lee HJ. Diagnosis and management of malignant pleural effusions: state of the art in 2017. J Thorac Dis. 2017;9(Suppl 10):S1111–22.PubMedPubMedCentral

Agalioti T, Giannou AD, Stathopoulos GT. Pleural involvement in lung cancer. J Thorac Dis. 2015;7(6):1021–30.PubMedPubMedCentral

Biaoxue R, Hui P, Wenlong G, Shuanying Y. Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion. Sci Rep. 2016;6:39355.PubMedPubMedCentral

Biaoxue R, Xiguang C, Hua L, Wenlong G, Shuanying Y. Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis. BMC Cancer. 2016;16(1):888.PubMedPubMedCentral

Davies HE, Lee YC. Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med. 2013;19(4):374–9.PubMed

Murwani R, Hodgkinson S, Armati P. Tumor necrosis factor alpha and interleukin-6 mRNA expression in neonatal Lewis rat Schwann cells and a neonatal rat Schwann cell line following interferon gamma stimulation. J Neuroimmunol. 1996;71(1–2):65–71.PubMed

Vanamee ES, Faustman DL. Structural principles of tumor necrosis factor superfamily signaling. Sci Signal. 2018;11(511):eaao4910.

Hua Z, Qing B, Hongxuan R. Effect of rmhTNF and DDP combination in the treatment of malignant pleural effusion caused by lung cancer (in Chinese). Heibei Med J. 2010;32(9):1104–5.

10.

Haiyan C, Yulong W, Lixin L, Tao H, Zhijun Z. Clinical observation of cisplatin and tumor necrosis factor treating pleural effusion of lung cancer (in Chinese). Shanxi Med J. 2015;44(1):68–9.

11.

Biaoxue R, Shuanying Y. Tissue or blood: which is more suitable for detection of EGFR mutations in non-small cell lung cancer? Int J Biol Markers. 2018;33(1):40–8.PubMed

12.

Jin L, Wei S, Tao Y, Jinzi H. Clinical observation of highly agglutinative staphlococcin, tumor necorsis factor and Cisplatin in the treatment of malignant pleural effusion caused by lung adenocarcinoma (in Chinese). China Med Herald. 2015;12(14):86–9.

13.

Yanhao W. Treatment of malignant pleural effusion of lung cancer by perfusion of recombinant human tumor necrosis factor in pleural cavity (in Chinese). China Med Herald. 2006;3(29):102–3.

14.

Yang D, Yi P, Xin D. Observation of malignant pleural effusion in elderly patients treated with human tumor necrosis factor and cisplatin (in Chinese). Chinese J Clin (Electronic Edition). 2015;9(21):4022–4.

15.

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.PubMed

16.

Kim JH, Kim BJ, Jang HJ, Kim HS. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review. Cancer Chemother Pharmacol. 2017;80(4):729–35.PubMed

17.

Mazumdar M, Smith A, Schwartz LH. A statistical simulation study finds discordance between WHO criteria and RECIST guideline. J Clin Epidemiol. 2004;57(4):358–65.PubMed

18.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.PubMedPubMedCentral

19.

Chun W, Yanfeng Y, Xiaodong F, Liqun Z. Clinical observation of recombinant human tumor necrosis factor alpha by intrapleuralperfusion in the treatment of malignant pleural effusion in elderly patients with lung cancer (in Chinese). Oncology Progress. 2016;14(1):84–6.

20.

Do W, Xiaomei S, Huanyi L, Tao Z, Jingjing P. Reconstructed and modified human tumor necrosis factor infusion in the treatment of lung cancer pleural effusion (in Chinese). Chinese J Lung Cancer. 2005;8(5):474.

21.

Hua Z, Jinjing P, Lifeng H, Hong Y. Clinical study of rmhTNF combined with PDD in the treatment of malignant pleural effusion caused by non small cell lung cancer in the elderly tin miners (in Chinese). Chinese Foreign Med Res. 2017;15(7):15–7.

22.

Shimeng F, Huashan Y. Clinical observation of reconstructed and modified human tumor necrosis factor and cisplatin intrathoracic injection for cancerous pleural effusion (in Chinese). J Weifang Med College. 2010;32(4):303–4.

23.

Tao H, Xiaoling C, Yuming H, Yujian T. The therapeutic effect of rmh-TNF combined cisplatin in treating lung cancer with malignant pleural effusion (in Chinese). China Modern Med. 2016;23(2):47–9.

24.

Xiqiang W, Yaling X. Therapeutic effect of tumor necrosis factor on malignant pleural effusion of lung cancer (in Chinese). Chinese J Gen Pract. 2010;8(8):999–1000.

25.

Yuquan L, Mingli T, Xianjun L, Weishun L, Huaiding L, Guoshi L. The clinical value of cisplatin combined with recombinant human tumor necrosis factor in the treatment of malignant pleural effusion caused by lung cancer (in Chinese). J Clin Intern Med. 2005;22(10):714–5.

26.

Zhijun W, Hongbing X, Yuanhui W, Aihua Z. Clinical observation on rmhTNF plus cisplatin compared with cisplatin alone in the treatmental of malignant paeural cavity effusion (in Chinese). Modern Oncol. 2007;15(2):202–3.

27.

Yasutake N, Matsuzaki T, Kimura K, Hashimoto S, Yokokura T, Yoshikai Y. The role of tumor necrosis factor (TNF)-alpha in the antitumor effect of intrapleural injection of lactobacillus casei strain Shirota in mice. Med Microbiol Immunol. 1999;188(1):9–14.PubMed

28.

Jakob J, Hohenberger P. Role of isolated limb perfusion with recombinant human tumor necrosis factor alpha and melphalan in locally advanced extremity soft tissue sarcoma. Cancer. 2016;122(17):2624–32.PubMed

29.

Moritz T, Niederle N, Baumann J, May D, Kurschel E, Osieka R, Kempeni J, Schlick E, Schmidt CG. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease. Cancer Immunol Immunother. 1989;29(2):144–50.PubMed

30.

van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11(4):397–408.PubMed

31.

Muret J, Yacoub M, Terrier P, Drusch F, Laplanche A, Gaudin C, Richon C, Le Pechoux C, Le Cesne A, Lejeune FJ, et al. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann Oncol. 2008;19(4):793–800.PubMed

32.

Corti A, Curnis F, Rossoni G, Marcucci F, Gregorc V. Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example. BioDrugs. 2013;27(6):591–603.PubMedPubMedCentral

33.

Shukui Q, Jun M, Jin L. Clinical consensus on clinical application of recombinant human tumor necrosis factor in the treatment of malignant thoracic and abdominal effusions. Chin Clin Oncol. 2018;23(1):67–72.

34.

Makimoto G, Miyahara N, Yoshikawa M, Taniguchi A, Kanehiro A, Tanimoto M, Kiura K. Heerfordt's syndrome associated with a high fever and elevation of TNF-alpha. Acta Med Okayama. 2016;70(4):273–7.PubMed

35.

Brito HO, Barbosa FL, Reis RC, Fraga D, Borges BS, Franco CR, Zampronio AR. Evidence of substance P autocrine circuitry that involves TNF-alpha, IL-6, and PGE2 in endogenous pyrogen-induced fever. J Neuroimmunol. 2016;293:1–7.PubMed

36.

Dinarello CA. Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. J Endotoxin Res. 2004;10(4):201–22.PubMed

Title: Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer
Authors: Tian Fu
Yong Lin
Qingdi Zeng
Wei Yao
Liping Han
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Pleural Effusion
Lung Cancer
Published in: BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-020-01210-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Pulmonary granulomas in a patient with positive ANCA and history of tuberculosis: case report

Does a pulmonary rehabilitation based ERAS program (PREP) affect pulmonary complication incidence, pulmonary function and quality of life after lung cancer surgery? Study protocol for a multicenter randomized controlled trial

Exploring characteristics of COPD patients with clinical improvement after integrated disease management or usual care: post-hoc analysis of the RECODE study

Correction to: Water-pipe smoke condensate increases the internalization of Mycobacterium Bovis of type II alveolar epithelial cells (A549)

In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs

Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page